Citadel Advisors
RCKT icon

Citadel Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Citadel Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,299,991
Closed -$5.17M – 14009
2025
Q4 		$4.56M Sell
1,299,991
-370,936
-22% -$1.27M ﹤0.01% 4426
2025
Q3 		$5.45M Buy
1,670,927
+1,514,877
+971% +$4.77M ﹤0.01% 4215
2025
Q2 		$382K Sell
156,050
-1,352,954
-90% -$6.85M ﹤0.01% 9251
2025
Q1 		$10.1M Sell
1,509,004
-2,613,820
-63% -$25.8M ﹤0.01% 2852
2024
Q4 		$51.8M Buy
4,122,824
+1,974,731
+92% +$29.7M 0.01% 1239
2024
Q3 		$39.7M Sell
2,148,093
-669,976
-24% -$13.7M 0.01% 1424
2024
Q2 		$60.7M Buy
2,818,069
+348,256
+14% +$8M 0.01% 1001
2024
Q1 		$66.5M Buy
2,469,813
+12,252
+0.5% +$348K 0.01% 997
2023
Q4 		$73.7M Sell
2,457,561
-220,940
-8% -$4.88M 0.01% 883
2023
Q3 		$54.9M Buy
2,678,501
+90,393
+3% +$1.64M 0.01% 994
2023
Q2 		$51.4M Sell
2,588,108
-70,841
-3% -$1.43M 0.01% 1024
2023
Q1 		$45.5M Buy
2,658,949
+56,269
+2% +$1.1M 0.01% 1155
2022
Q4 		$50.9M Buy
2,602,680
+838,759
+48% +$15.4M 0.01% 1107
2022
Q3 		$28.2M Buy
1,763,921
+256,082
+17% +$4M 0.01% 1544
2022
Q2 		$20.7M Sell
1,507,839
-278,416
-16% -$3.32M 0.01% 1817
2022
Q1 		$28.3M Buy
1,786,255
+93,289
+6% +$1.61M 0.01% 1606
2021
Q4 		$37M Buy
1,692,966
+393,990
+30% +$10.7M 0.01% 1426
2021
Q3 		$38.8M Buy
1,298,976
+501,297
+63% +$18.2M 0.01% 1326
2021
Q2 		$35.3M Buy
797,679
+110,881
+16% +$4.82M 0.01% 1439
2021
Q1 		$30.5M Sell
686,798
-632,105
-48% -$34.7M 0.01% 1494
2020
Q4 		$72.3M Buy
1,318,903
+207,094
+19% +$7.55M 0.02% 720
2020
Q3 		$25.4M Buy
1,111,809
+38,105
+4% +$939K 0.01% 1369
2020
Q2 		$22.5M Buy
1,073,704
+7,735
+0.7% +$139K 0.01% 1412
2020
Q1 		$14.9M Sell
1,065,969
-173,689
-14% -$3.44M 0.01% 1487
2019
Q4 		$28.2M Buy
1,239,658
+46,457
+4% +$776K 0.01% 1180
2019
Q3 		$13.9M Buy
1,193,201
+79,033
+7% +$981K 0.01% 1853
2019
Q2 		$16.7M Buy
1,114,168
+17,694
+2% +$309K 0.01% 1604
2019
Q1 		$19.2M Buy
1,096,474
+16,217
+2% +$256K 0.01% 1374
2018
Q4 		$16M Buy
1,080,257
+322,211
+43% +$5.35M 0.01% 1415
2018
Q3 		$18.7M Sell
758,046
-71,020
-9% -$1.54M 0.01% 1456
2018
Q2 		$16.3M Buy
829,066
+409,564
+98% +$7.75M 0.01% 1488
2018
Q1 		$7.87M Buy
419,502
+410,086
+4,355% +$6.69M ﹤0.01% 1959
2017
Q4 		$98K Buy
9,416
+5,368
+133% +$53.2K ﹤0.01% 7444
2017
Q3 		$29K Sell
4,048
-108
-3% -$494 ﹤0.01% 7293
2017
Q2 		$32K Sell
4,156
-1,334
-24% -$9.95K ﹤0.01% 7192
2017
Q1 		$44K Sell
5,490
-1,329
-19% -$8.94K ﹤0.01% 7069
2016
Q4 		$166K Buy
+6,819
New +$195K ﹤0.01% 6435
2016
Q3 		– Sell
-4,227
Closed -$126K – 7660
2016
Q2 		$126K Buy
+4,227
New +$149K ﹤0.01% 6094
2015
Q4 		– Sell
-8,180
Closed -$308K – 9097
2015
Q3 		$308K Buy
+8,180
New +$376K ﹤0.01% 5525

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's RCKT Position: Q1 2026 in Review

Citadel Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 1,299,991 shares — an estimated $5.17M sold.

Citadel Advisors first reported a position in RCKT in Q3 2015 and held it in 39 quarters. The position peaked at $73.7M in Q4 2023. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Citadel Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,299,991 Rocket Pharmaceuticals shares in Q1 2026, an estimated $5.17M.
  • Citadel Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 39 quarters.
  • Citadel Advisors's Rocket Pharmaceuticals position peaked at $73.7M in Q4 2023.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.